Elevance Health, Inc. shareholders rejected Shareholder proposal requesting an independent study on the impact of prohibiting corporate contributions to partisan 527 tax-exempt political groups at the 2026-05-13 meeting.
“4. Shareholder proposal requesting an independent study on the impact of prohibiting corporate contributions to partisan 527 tax-exempt political groups. The shareholder proposal requesting a study on the impact of prohibiting corporate contributions to partisan 527 tax-exempt political groups was not approved based upon the following votes: For Against Abstain Broker Non-Votes 15,587,160 162,924,290 1,292,319 14,637,570”
Shareholder Votes
Elevance Health, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-13 meeting.
“3. Ratification of the appointment of Ernst & Young LLP . The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based upon the following votes: For Against Abstain 175,183,332 19,141,697 116,310”
Shareholder Votes
Elevance Health, Inc. shareholders approved Advisory vote on the Company's executive compensation at the 2026-05-13 meeting.
“2. Advisory vote on the Company’s executive compensation . The advisory vote on the compensation of the Company’s named executive officers was approved based upon the following votes: For Against Abstain Broker Non-Votes 172,363,616 7,240,619 199,534 14,637,570”
Shareholder Votes
Elevance Health, Inc. shareholders approved Election of Directors at the 2026-05-13 meeting.
“1. Election of Directors . The following nominees for director were elected to serve three-year terms to expire at the Company’s annual meeting of shareholders in 2029 based on the following votes: Nominee For Against Abstain Broker Non-Votes Gail K. Boudreaux 177,978,713 1,714,229 110,827 14,637,570 Robert L. Dixon, Jr. 174,098,489 5,590,793 114,487 14,637,570 Deanna D. Strable 175,331,822 4,360,980 110,967 14,637,570”
Earnings Releases
Elevance Health, Inc. reported FY 2026 results: EPS at least $26.75. Guidance raised.
“FY 2026 adjusted diluted EPS 2 guidance raised to at least $26.75, supported by underlying business strength, actions to reduce medical costs, and increased visibility”
Earnings Releases
Elevance Health, Inc. reported first quarter 2026 results: revenue $49.5 billion, EPS $8.00. Guidance raised.
“ELEVANCE HEALTH REPORTS FIRST QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCE • 1Q 2026 operating revenue of $49.5 billion, up 1.5% from 1Q 2025 • 1Q 2026 diluted EPS 1 of $8.00; adjusted diluted EPS 2 of $12.58 driven by strong operating results and ~$1 per share of non-recurring investment income”
Shareholder Votes
Elevance Health, Inc. shareholders rejected Shareholder proposal requesting annual political activity reporting from certain third parties prior to the Company donating to the organizations at the 2024-05-15 meeting.
“Shareholder proposal requesting annual political activity reporting from certain third parties prior to the Company donating to the organizations. The shareholder proposal requesting annual political activity reporting from third parties prior to the Company donating to the organization was not approved based upon the following votes:”
Shareholder Votes
Elevance Health, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP at the 2024-05-15 meeting.
“Ratification of the appointment of Ernst & Young LLP. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2024 was ratified based upon the following votes:”
Shareholder Votes
Elevance Health, Inc. shareholders approved Advisory vote on the Company’s executive compensation at the 2024-05-15 meeting.
“Advisory vote on the Company’s executive compensation. The advisory vote on the compensation of the Company’s named executive officers was approved based upon the following votes:”
Shareholder Votes
Elevance Health, Inc. shareholders approved Election of Directors at the 2024-05-15 meeting.
“Election of Directors. The following nominees for director were elected to serve three-year terms to expire at the Company’s annual meeting of shareholders in 2027 based on the following votes:”
Earnings Releases
Elevance Health, Inc. reported the quarter ended March 31, 2024 results: revenue $42.3 billion, EPS $9.59. Guidance raised.
“language in such filings. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 EARNINGS RELEASE ELEVANCE HEALTH REPORTS FIRST QUARTER 2024 RESULTS • 1Q 2024 operating revenue of $42.3 billion, up 0.9% from 1Q 2023 • 1Q 2024 diluted EPS 1 of $9.59, up 15.5% from 1Q 2023 and adjusted diluted EPS 2 of $10.64, up 12.5% • FY 2024 diluted EPS and adjusted diluted EPS”
Earnings Releases
Elevance Health, Inc. reported FY 2024 results: EPS greater than $34.29. Guidance initiated.
“Projected FY 2024 GAAP diluted EPS and adjusted diluted EPS 2 of greater than $34.29 and $37.10 per share, respectively”
“FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 • 4Q 2023 GAAP diluted EPS 1 of $3.63, up 1.1% from 4Q 2022 and adjusted diluted EPS 2 of $5.62, up 15.2%; FY 2023 GAAP diluted EPS of $25.22, up 3.9% from FY 2022”
“4Q 2023 operating revenue of $42.5 billion, up 7.0% from 4Q 2022; FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 • 4Q 2023 GAAP diluted EPS 1 of $3.63, up 1.1% from 4Q 2022”
Earnings Releases
Elevance Health, Inc. reported the quarter ended September 30, 2023 results: revenue $42.5 billion, net income $5.45 per share, EPS $5.45 per share. Guidance raised.
“third quarter of 2023, medical membership decreased by 664 thousand driven by attrition in Medicaid due to the aforementioned dynamics. Operating Revenue: Operating revenue was $42.5 billion in the third quarter of 2023, an increase of $2.9 billion, or 7.2 percent year-over-year. The increase was primarily driven by higher premium revenue in our Health Benefits”
Governance Changes
Elevance Health, Inc.: Amended bylaws to update procedural and informational requirements for director nominations in response to SEC universal proxy rules (effective 2023-10-04).
“On October 4, 2023, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) approved the amendment of the Company’s Bylaws (as so amended, the “Bylaws”) to, among other things, update procedural and informational requirements applicable to director nominations submitted by shareholders in light of the Securities and Exchange Commission’s adoption of “universal proxy” rules as set forth in Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).”
John Gallina retired as Chief Financial Officer at Elevance Health, Inc..
“Mr. Kaye succeeds John Gallina, who, after nearly thirty years of dedicated services to the Company, has decided to retire as CFO.”
Mark Kaye was appointed as Executive Vice President and Chief Financial Officer at Elevance Health, Inc..
“On August 8, 2023, Elevance Health, Inc. (the “Company”) announced that Mark Kaye has been named Executive Vice President and Chief Financial Officer (“CFO”) of the Company, effective November 1, 2023 (the “Transition Date”).”
Earnings Releases
Elevance Health, Inc. reported 2023 results: EPS GAAP net income to be greater than $29.09 per share in 2023, and adjusted net income to be greater than $32.85 per share. Guidance raised.
“Given the strong performance in the first half of the year and momentum across Elevance Health, we now expect GAAP net income to be greater than $29.09 per share in 2023, and adjusted net income to be greater than $32.85 per share.”
Earnings Releases
Elevance Health, Inc. reported the quarter ended June 30, 2023 results: revenue $43.4 billion, EPS $7.79 per share.
“Second quarter GAAP net income was $7.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $9.04* per share. • Operating revenue grew 12.7% year-over-year to $43.4 billion”
Earnings Releases
Elevance Health, Inc. reported the quarter ended March 31, 2023 results: revenue $41.9 billion, net income $8.30 per share, EPS $8.30 per share. Guidance raised.
“was $8.30 per share, including net negative adjustment items of $1.16 per share. Adjusted net income was $9.46* per share. • Operating revenue grew 10.6% year-over-year to $41.9 billion • Operating gain grew 16.6% year-over-year to $2.8 billion • Medical enrollment increased 1.3 million members year-over-year to 48.1 million members • Second quarter 2023”
Gloria M. McCarthy changed role as Special Advisor to the Chief Executive Officer at Elevance Health, Inc..
“Elevance Health, Inc. (the “Company”) is today announcing that Gloria M. McCarthy will assume the new role of Special Advisor to the Chief Executive Officer and will no longer serve as Executive Vice President and Chief Administrative Officer of the Company, effective April 1, 2023.”
Earnings Releases
Elevance Health, Inc. reported year ending December 31, 2023 results: EPS greater than $29.80 per share. Guidance initiated.
“The Company expects GAAP net income to be greater than $29.80 per share in 2023, and adjusted net income to be greater than $32.60 per share.”
Earnings Releases
Elevance Health, Inc. reported year ended December 31, 2022 results: revenue $156 billion, EPS $24.81 per share.
“• Fourth quarter and full year GAAP net income was $3.93 and $24.81 per share • Fourth quarter and full year adjusted net income was $5.23* and $29.07* per share • Full year operating revenue grew 13.7% year-over-year to $156 billion • Full year operating gain grew 12.9% year-over-year to $8.5 billion • Medical enrollment increased 2.2 million members year-over-year to 47.5 million members • Quarterly dividend increased by 16% to $1.48 per share”
Earnings Releases
Elevance Health, Inc. reported quarter ended December 31, 2022 results: EPS $3.93 per share.
“GAAP net income was $3.93 per share in the fourth quarter, including net negative adjustment items of $1.30 per share.”
Deanna Strable-Soethout was elected as Director at Elevance Health, Inc..
“On October 24, 2022, the Board of Directors (the “Board”) of Elevance Health, Inc. (the “Company”) elected Deanna Strable-Soethout to serve as an independent director effective November 1, 2022”
Susan Dodson DeVore was elected as independent director at Elevance Health, Inc..
“On August 3, 2021, the Board of Directors (the “Board”) of the Company elected Susan Dodson DeVore to serve as an independent director effective immediately, with a term expiring at the Company’s 2022 annual meeting of shareholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.